Marco Ruella

13.3k total citations · 2 hit papers
124 papers, 4.0k citations indexed

About

Marco Ruella is a scholar working on Oncology, Molecular Biology and Immunology. According to data from OpenAlex, Marco Ruella has authored 124 papers receiving a total of 4.0k indexed citations (citations by other indexed papers that have themselves been cited), including 104 papers in Oncology, 39 papers in Molecular Biology and 32 papers in Immunology. Recurrent topics in Marco Ruella's work include CAR-T cell therapy research (95 papers), Lymphoma Diagnosis and Treatment (24 papers) and Immune Cell Function and Interaction (21 papers). Marco Ruella is often cited by papers focused on CAR-T cell therapy research (95 papers), Lymphoma Diagnosis and Treatment (24 papers) and Immune Cell Function and Interaction (21 papers). Marco Ruella collaborates with scholars based in United States, Italy and France. Marco Ruella's co-authors include Carl H. June, Saad S. Kenderian, Marcela V. Maus, Saar Gill, Olga Shestova, Michael Kalos, Sònia Guedan, John Scholler, Martin Carroll and Michael Klichinsky and has published in prestigious journals such as Nature Communications, The Journal of Experimental Medicine and Journal of Clinical Oncology.

In The Last Decade

Marco Ruella

116 papers receiving 4.0k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Immunogenicity of CAR T cells in cancer therapy

2021 208 citations Marco Ruella et al. profile →
Deletion of the inhibitory co-receptor CTLA-4 enhances and invigorates chimeric antigen receptor T cells

2023 104 citations Sangya Agarwal, Shunichiro Kuramitsu et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Marco Ruella United States	29	3.2k	1.3k	1.3k	1.1k	809	124	4.0k
Bambi Grilley United States	21	3.7k 1.1×	1.5k 1.1×	1.2k 1.0×	1.5k 1.4×	920 1.1×	69	4.4k
Brian G. Till United States	26	2.9k 0.9×	1.0k 0.8×	988 0.8×	725 0.7×	725 0.9×	135	3.5k
Joseph A. Fraietta United States	25	3.6k 1.1×	2.0k 1.5×	1.7k 1.3×	924 0.9×	1.0k 1.3×	80	4.9k
Vanessa Gonzalez United States	8	5.0k 1.6×	1.8k 1.4×	1.5k 1.2×	1.5k 1.4×	1.4k 1.7×	20	5.6k
Matthew J. Frigault United States	25	2.9k 0.9×	851 0.7×	885 0.7×	717 0.7×	951 1.2×	131	3.4k
Karin Straathof United States	23	3.6k 1.1×	1.9k 1.4×	1.2k 1.0×	1.4k 1.3×	793 1.0×	38	4.6k
Meng-Fen Wu United States	16	2.4k 0.7×	1.0k 0.8×	815 0.6×	743 0.7×	627 0.8×	18	2.9k
Hanren Dai China	28	3.4k 1.0×	1.3k 1.0×	992 0.8×	831 0.8×	954 1.2×	51	3.9k
Saad S. Kenderian United States	25	2.1k 0.6×	790 0.6×	737 0.6×	647 0.6×	537 0.7×	149	2.9k
Enli Liu United States	19	4.5k 1.4×	2.1k 1.6×	1.8k 1.5×	1.7k 1.6×	1.3k 1.6×	31	5.6k

Countries citing papers authored by Marco Ruella

Since Specialization

Citations

This map shows the geographic impact of Marco Ruella's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Marco Ruella with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Marco Ruella more than expected).

Fields of papers citing papers by Marco Ruella

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Marco Ruella. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Marco Ruella. The network helps show where Marco Ruella may publish in the future.

Co-authorship network of co-authors of Marco Ruella

This figure shows the co-authorship network connecting the top 25 collaborators of Marco Ruella. A scholar is included among the top collaborators of Marco Ruella based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Marco Ruella. Marco Ruella is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Isshiki, Yusuke, Patrizia Porazzi, Ari Melnick, Marco Ruella, & Wendy Béguelin. (2023). EZH2 INHIBITION ENHANCES CAR T ANTITUMOR EFFECT BY INDUCING LYMPHOMA IMMUNOGENICITY AND ENHANCING T CELL FUNCTION. Hematological Oncology. 41(S2). 228–228.

Ruella, Marco. (2023). ALKemy to enhance chimeric antigen receptor T cell immunotherapy for neuroblastoma. Cancer Cell. 41(12). 2016–2018. 1 indexed citations

Snook, Adam E., Guido Ghilardi, Steven Yang, et al.. (2023). Senza5 TM CART5: An Autologous CD5-Deleted Anti-CD5 CART Product with Enhanced Anti-T-Cell Lymphoma Activity. Blood. 142(Supplement 1). 3462–3462. 1 indexed citations

Kuramitsu, Shunichiro, Tong Da, Sangya Agarwal, et al.. (2023). Identifying highly active anti-CCR4 CAR T cells for the treatment of T-cell lymphoma. Blood Advances. 7(14). 3416–3430. 27 indexed citations

Anderson, Kristin G., David A. Braun, Aitziber Buqué, et al.. (2023). Leveraging immune resistance archetypes in solid cancer to inform next-generation anticancer therapies. Journal for ImmunoTherapy of Cancer. 11(6). e006533–e006533. 12 indexed citations

Tang, Yan, Wei Liu, Omar Johnson, et al.. (2023). Exploiting the CD200-CD200R immune checkpoint axis in multiple myeloma to enhance CAR T-cell therapy. Blood. 143(2). 139–151. 9 indexed citations

Tavakkoli, Montreh, Elise A. Chong, Marco Ruella, et al.. (2023). CD5 Expression in Mature T Cell Lymphoma. Blood. 142(Supplement 1). 6195–6195. 1 indexed citations

Heard, Amanda, John M. Warrington, John Lattin, et al.. (2022). Antigen glycosylation regulates efficacy of CAR T cells targeting CD19. Nature Communications. 13(1). 3367–3367. 40 indexed citations

Guruprasad, Puneeth, Yong Gu Lee, Ki Hyun Kim, & Marco Ruella. (2020). The current landscape of single-cell transcriptomics for cancer immunotherapy. The Journal of Experimental Medicine. 218(1). 38 indexed citations

10.

Ruella, Marco, David M. Barrett, Olga Shestova, et al.. (2019). A cellular antidote to specifically deplete anti-CD19 chimeric antigen receptor–positive cells. Blood. 135(7). 505–509. 24 indexed citations

11.

Ascierto, Paolo A., James Brugarolas, Luigi Buonaguro, et al.. (2018). Perspectives in immunotherapy: meeting report from the Immunotherapy Bridge (29-30 November, 2017, Naples, Italy). Journal for ImmunoTherapy of Cancer. 6(1). 69–69. 9 indexed citations

12.

Watanabe, Keisuke, Yanping Luo, Tong Da, et al.. (2018). Pancreatic cancer therapy with combined mesothelin-redirected chimeric antigen receptor T cells and cytokine-armed oncolytic adenoviruses. JCI Insight. 3(7). 215 indexed citations

13.

Ruella, Marco, Michael Klichinsky, Saad S. Kenderian, et al.. (2017). Overcoming the Immunosuppressive Tumor Microenvironment of Hodgkin Lymphoma Using Chimeric Antigen Receptor T Cells. Cancer Discovery. 7(10). 1154–1167. 153 indexed citations

14.

Singh, Nathan, Junwei Shi, Carl H. June, & Marco Ruella. (2017). Genome-Editing Technologies in Adoptive T Cell Immunotherapy for Cancer. Current Hematologic Malignancy Reports. 12(6). 522–529. 64 indexed citations

15.

Ruella, Marco, Saad S. Kenderian, Olga Shestova, et al.. (2016). The Addition of the BTK Inhibitor Ibrutinib to Anti-CD19 Chimeric Antigen Receptor T Cells (CART19) Improves Responses against Mantle Cell Lymphoma. Clinical Cancer Research. 22(11). 2684–2696. 141 indexed citations

16.

Ruella, Marco, Saad S. Kenderian, Olga Shestova, et al.. (2016). Kinase Inhibitor Ibrutinib Prevents Cytokine-Release Syndrome after Anti-CD19 Chimeric Antigen Receptor T Cells (CART) for B Cell Neoplasms. Blood. 128(22). 2159–2159. 8 indexed citations

17.

Kenderian, Saad S., Marco Ruella, Olga Shestova, et al.. (2016). Ruxolitinib Prevents Cytokine Release Syndrome after CART Cell Therapy without Impairing the Anti-Tumor Effect in a Xenograft Model. Blood. 128(22). 652–652. 31 indexed citations

18.

Gill, Saar, Sarah K. Tasian, Marco Ruella, et al.. (2014). Preclinical targeting of human acute myeloid leukemia and myeloablation using chimeric antigen receptor–modified T cells. Blood. 123(15). 2343–2354. 363 indexed citations

19.

Tarella, Corrado, Angela Gueli, Federica Delaini, et al.. (2014). Rate of Primary Refractory Disease in B and T-Cell Non-Hodgkin’s Lymphoma: Correlation with Long-Term Survival. PLoS ONE. 9(9). e106745–e106745. 17 indexed citations

20.

Buttiglieri, Stefano, Marco Ruella, Alessandra Risso, et al.. (2011). The aging effect of chemotherapy on cultured human mesenchymal stem cells. Experimental Hematology. 39(12). 1171–1181. 57 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact